PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

The study is conducted to evaluate the efficacy, safety and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 504 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease
Actual Study Start Date: February 18, 2019
Estimated Primary Completion Date: February 2021
Estimated Study Completion Date: February 2021

Arms:
- Experimental: K0706, low dose
- Experimental: K0706, high dose
- Placebo Comparator: Placebo, placebo capsules